Climb Bio, Inc. (CLYM) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
Tweet
Share
E-mailGet Alerts CLYM Hot Sheet
Join SI Premium – FREE
Climb Bio, Inc. (NASDAQ: CLYM) reported Q2 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21).
For earnings history and earnings-related data on Climb Bio, Inc. (CLYM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why Ed Yardeni says the best market entry points are still to come
- CEMEX, S.A.B. de C.V. (CX) Tops Q3 EPS by 4c
- GameSquare acquires FanEngine IP assets, targets $150M revenue in 2027
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
